



CLIENT CODE : C000138394

**CLIENT'S NAME AND ADDRESS :**  
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
F-703, F-703, LADO SARAI, MEHRAULI  
SOUTH WEST DELHI  
NEW DELHI 110030  
DELHI INDIA  
8800465156

SRL Ltd  
S.K. Tower, Hari Niwas, LBS Marg  
THANE, 400602  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956  
Email : customercare.thane@srl.in

**PATIENT NAME : ANIRUDDHA ANANT MIRASHI**PATIENT ID : **ANIRM170194181**ACCESSION NO : **0181VJ000691** AGE : 28 Years SEX : Male

ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18

REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF

CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

**MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE****BLOOD COUNTS, EDTA WHOLE BLOOD**

HEMOGLOBIN	13.9	13.0 - 17.0	g/dL
METHOD : SLS- HEMOGLOBIN DETECTION METHOD			
RED BLOOD CELL COUNT	5.32	4.5 - 5.5	mil/ $\mu$ L
METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION			
WHITE BLOOD CELL COUNT	5.01	4.0 - 10.0	thou/ $\mu$ L
METHOD : FLUORESCENCE FLOW CYTOMETRY			
PLATELET COUNT	377	150 - 410	thou/ $\mu$ L
METHOD : HYDRODYNAMIC FOCUSING BY DC DETECTION			

**RBC AND PLATELET INDICES**

HEMATOCRIT	45.5	40.0 - 50.0	%
METHOD : CUMULATIVE PULSE HEIGHT DETECTION METHOD			
MEAN CORPUSCULAR VOL	85.5	83.0 - 101.0	fL
METHOD : CALCULATED FROM RBC & HCT			
MEAN CORPUSCULAR HGB.	<b>26.1</b>	<b>Low</b> 27.0 - 32.0	pg
METHOD : CALCULATED FROM THE RBC & HGB			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION	<b>30.5</b>	<b>Low</b> 31.5 - 34.5	g/dL
METHOD : CALCULATED FROM THE HGB & HCT			
MENTZER INDEX	16.1		
RED CELL DISTRIBUTION WIDTH	<b>14.6</b>	<b>High</b> 11.6 - 14.0	%
METHOD : CALCULATED FROM RBC SIZE DISTRIBUTION CURVE			
MEAN PLATELET VOLUME	9.4	6.8 - 10.9	fL
METHOD : CALCULATED FROM PLATELET COUNT & PLATELET HEMATOCRIT			

**WBC DIFFERENTIAL COUNT**

SEGMENTED NEUTROPHILS	57	40 - 80	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE NEUTROPHIL COUNT	2.86	2.0 - 7.0	thou/ $\mu$ L
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			
LYMPHOCYTES	31	20 - 40	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			
ABSOLUTE LYMPHOCYTE COUNT	1.57	1.0 - 3.0	thou/ $\mu$ L
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	1.8		
EOSINOPHILS	4	1 - 6	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING			





CLIENT CODE : C000138394

## CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
F-703, F-703, LADO SARAI, MEHRAULI  
SOUTH WEST DELHI  
NEW DELHI 110030  
DELHI INDIA  
8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email : customercare.thane@srl.in

PATIENT NAME : ANIRUDDHA ANANT MIRASHI

PATIENT ID : ANIRM170194181

ACCESSION NO : 0181VJ000691 AGE : 28 Years SEX : Male

ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18

REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF

CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
ABSOLUTE EOSINOPHIL COUNT		0.21	0.02 - 0.50	thou/ $\mu$ L
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
MONOCYTES		8	2 - 10	%
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
ABSOLUTE MONOCYTE COUNT		0.41	0.2 - 1.0	thou/ $\mu$ L
METHOD : FLOW CYTOMETRY WITH LIGHT SCATTERING				
DIFFERENTIAL COUNT PERFORMED ON:		EDTA SMEAR		
<b>MORPHOLOGY</b>				
RBC		NORMOCYTIC NORMOCHROMIC		
WBC		NORMAL MORPHOLOGY		
METHOD : MICROSCOPIC EXAMINATION				
PLATELETS		ADEQUATE		
<b>ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD</b>				
SEDIMENTATION RATE (ESR)		15	High 0 - 14	mm at 1 hr
METHOD : WESTEREGREN METHOD				
<b>GLUCOSE FASTING, FLUORIDE PLASMA</b>				
GLUCOSE, FASTING, PLASMA		89	Normal 75 - 99 Pre-diabetics: 100 - 125 Diabetic: > or = 126	mg/dL
METHOD : ENZYMATIC REFERENCE METHOD WITH HEXOKINASE				
<b>GLYCOSYLATED HEMOGLOBIN (HBA1C), EDTA WHOLE BLOOD</b>				
GLYCOSYLATED HEMOGLOBIN (HBA1C)		5.2	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%
METHOD : HPLC				
MEAN PLASMA GLUCOSE		102.5	< 116.0	mg/dL
METHOD : CALCULATED PARAMETER				
<b>GLUCOSE, POST-PRANDIAL, PLASMA</b>				
GLUCOSE, POST-PRANDIAL, PLASMA		96	70 - 139	mg/dL
METHOD : ENZYMATIC REFERENCE METHOD WITH HEXOKINASE				
<b>LIPID PROFILE, SERUM</b>				
CHOLESTEROL		174	Desirable cholesterol level < 200 Borderline high cholesterol 200 - 239 High cholesterol > / = 240	mg/dL





CLIENT CODE : C000138394

## CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
F-703, F-703, LADO SARAI, MEHRAULI  
SOUTH WEST DELHI  
NEW DELHI 110030  
DELHI INDIA  
8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email : customercare.thane@srl.in

PATIENT NAME : ANIRUDDHA ANANT MIRASHI

PATIENT ID : ANIRM170194181

ACCESSION NO : 0181VJ000691 AGE : 28 Years SEX : Male

ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18

REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF

CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
METHOD : ENZYMATIC COLORIMETRIC ASSAY				
TRIGLYCERIDES		127	Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
METHOD : ENZYMATIC COLORIMETRIC ASSAY				
HDL CHOLESTEROL		43	Low HDL Cholesterol <40 High HDL Cholesterol >/= 60	mg/dL
METHOD : ENZYMATIC, COLORIMETRIC				
CHOLESTEROL LDL		106	High Adult levels: Optimal < 100 Near optimal/above optimal: 100-129 Borderline high : 130-159 High : 160-189 Very high : = 190	mg/dL
METHOD : ENZYMATIC COLORIMETRIC ASSAY				
NON HDL CHOLESTEROL		131	High Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL
CHOL/HDL RATIO		4.1	Low Risk : 3.3 - 4.4 Average Risk : 4.5 - 7.0 Moderate Risk : 7.1 - 11.0 High Risk : > 11.0	
LDL/HDL RATIO		2.5	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderate Risk >6.0 High Risk	
VERY LOW DENSITY LIPOPROTEIN		25.4	< OR = 30.0	mg/dL
<b>LIVER FUNCTION PROFILE, SERUM</b>				
BILIRUBIN, TOTAL		0.42		mg/dL
BILIRUBIN, DIRECT		0.19	< 0.30	mg/dL
BILIRUBIN, INDIRECT		0.23	0.1 - 1.0	mg/dL
TOTAL PROTEIN		7.8	6.0 - 8.0	g/dL
METHOD : COLORIMETRIC				
ALBUMIN		4.9	3.97 - 4.94	g/dL
METHOD : COLORIMETRIC				
GLOBULIN		2.9	2.0 - 3.5	g/dL
ALBUMIN/GLOBULIN RATIO		1.7	1.0 - 2.1	RATIO
ASPARTATE AMINOTRANSFERASE (AST/SGOT)		40	< OR = 50	U/L
METHOD : UV ABSORBANCE				





CLIENT CODE : C000138394

## CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
F-703, F-703, LADO SARAI, MEHRAULI  
SOUTH WEST DELHI  
NEW DELHI 110030  
DELHI INDIA  
8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email : customercare.thane@srl.in

PATIENT NAME : ANIRUDDHA ANANT MIRASHI

PATIENT ID : ANIRM170194181

ACCESSION NO : 0181VJ000691 AGE : 28 Years SEX : Male

ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18

REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF

CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
ALANINE AMINOTRANSFERASE (ALT/SGPT)		<b>84</b>	<b>High</b> < OR = 50	U/L
METHOD : UV ABSORBANCE				
ALKALINE PHOSPHATASE		68	40 - 129	U/L
METHOD : COLORIMETRIC				
GAMMA GLUTAMYL TRANSFERASE (GGT)		33	0 - 60	U/L
METHOD : ENZYMATIC, COLORIMETRIC				
LACTATE DEHYDROGENASE		178	125 - 220	U/L
METHOD : UV ABSORBANCE				
<b>BLOOD UREA NITROGEN (BUN), SERUM</b>				
BLOOD UREA NITROGEN		11	6 - 20	mg/dL
METHOD : ENZYMATIC ASSAY				
<b>CREATININE, SERUM</b>				
CREATININE		0.89	0.7 - 1.2	mg/dL
METHOD : COLORIMETRIC				
<b>BUN/CREAT RATIO</b>				
BUN/CREAT RATIO		12.36	8.0 - 15.0	
<b>URIC ACID, SERUM</b>				
URIC ACID		4.9	3.4 - 7.0	mg/dL
METHOD : ENZYMATIC COLORIMETRIC ASSAY				
<b>TOTAL PROTEIN, SERUM</b>				
TOTAL PROTEIN		7.8	6.0 - 8.0	g/dL
METHOD : COLORIMETRIC				
<b>ALBUMIN, SERUM</b>				
ALBUMIN		4.9	3.97 - 4.94	g/dL
METHOD : COLORIMETRIC				
<b>GLOBULIN</b>				
GLOBULIN		2.9	2.0 - 3.5	g/dL
<b>ELECTROLYTES (NA/K/CL), SERUM</b>				
SODIUM		137	136 - 145	mmol/L
POTASSIUM		4.34	3.5 - 5.1	mmol/L
CHLORIDE		98	98 - 107	mmol/L
<b>PHYSICAL EXAMINATION, URINE</b>				
COLOR		PALE YELLOW		
METHOD : VISUAL INSPECTION				
APPEARANCE		CLEAR		
METHOD : VISUAL INSPECTION				
SPECIFIC GRAVITY		1.010	1.003 - 1.035	





CLIENT CODE : C000138394

**CLIENT'S NAME AND ADDRESS :**  
ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
F-703, F-703, LADO SARAI, MEHRAULI  
SOUTH WEST DELHI  
NEW DELHI 110030  
DELHI INDIA  
8800465156

SRL Ltd  
S.K. Tower, Hari Niwas, LBS Marg  
THANE, 400602  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956  
Email : customercare.thane@srl.in

**PATIENT NAME : ANIRUDDHA ANANT MIRASHI**PATIENT ID : **ANIRM170194181**ACCESSION NO : **0181VJ000691** AGE : 28 Years SEX : Male

ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18

REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF

CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

METHOD : IONIC CONCENTRATION METHOD

**CHEMICAL EXAMINATION, URINE**

PH	5.5	4.7 - 7.5	
METHOD : DOUBLE INDICATOR PRINCIPLE			
PROTEIN	NOT DETECTED	NOT DETECTED	
METHOD : TETRA BROMOPHENOL BLUE/SULFOSALICYLIC ACID			
GLUCOSE	NOT DETECTED	NOT DETECTED	
METHOD : GLUCOSE OXIDASE PEROXIDASE			
KETONES	NOT DETECTED	NOT DETECTED	
METHOD : NITROPRUSSIDE REACTION			
BLOOD	NOT DETECTED	NOT DETECTED	
METHOD : PEROXIDASE			
UROBILINOGEN	NORMAL	NORMAL	
METHOD : MODIFIED EHRLICH REACTION			
NITRITE	NOT DETECTED	NOT DETECTED	
METHOD : 1,2,3,4-TETRAHYDROBENZO(H)QUINOLIN-3-OL			
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	

**MICROSCOPIC EXAMINATION, URINE**

PUS CELL (WBC'S)	1-2	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
EPITHELIAL CELLS	0-1	0-5	/HPF
METHOD : MICROSCOPIC EXAMINATION			
ERYTHROCYTES (RBC'S)	NOT DETECTED	NOT DETECTED	/HPF
METHOD : MICROSCOPIC EXAMINATION			
CASTS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
CRYSTALS	NOT DETECTED		
METHOD : MICROSCOPIC EXAMINATION			
BACTERIA	NOT DETECTED	NOT DETECTED	
METHOD : MICROSCOPIC EXAMINATION			
YEAST	NOT DETECTED	NOT DETECTED	

**THYROID PANEL, SERUM**

T3	147.0	80 - 200	ng/dL
METHOD : ELECTROCHEMILUMINESCENCE			
T4	7.81	5.1 - 14.1	µg/dL
METHOD : ELECTROCHEMILUMINESCENCE			
TSH 3RD GENERATION	1.840	0.27 - 4.2	µIU/mL
METHOD : ELECTROCHEMILUMINESCENCE			





CLIENT CODE : C000138394

## CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
F-703, F-703, LADO SARAI, MEHRAULI  
SOUTH WEST DELHI  
NEW DELHI 110030  
DELHI INDIA  
8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email : customercare.thane@srl.in

PATIENT NAME : ANIRUDDHA ANANT MIRASHI

PATIENT ID : ANIRM170194181

ACCESSION NO : 0181VJ000691 AGE : 28 Years SEX : Male

ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18

REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF

CLIENT PATIENT ID :

Test Report Status	Results	Biological Reference Interval	Units
Final			

## ABO GROUP &amp; RH TYPE, EDTA WHOLE BLOOD

ABO GROUP TYPE A

METHOD : GEL COLUMN AGGLUTINATION METHOD.

RH TYPE POSITIVE

METHOD : GEL COLUMN AGGLUTINATION METHOD.

## XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

## TMT OR ECHO

TMT OR ECHO NEGATIVE

## ECG

ECG WITHIN NORMAL LIMITS

## MEDICAL HISTORY

RELEVANT PRESENT HISTORY NOT SIGNIFICANT

RELEVANT PAST HISTORY NOT SIGNIFICANT

RELEVANT PERSONAL HISTORY MARRIED / VEG. DIET / NO ALLERGIES / NO SMOKING / NO ALCOHOL.

RELEVANT FAMILY HISTORY GRANDMOTHER: -DIABETES

HISTORY OF MEDICATIONS MOTHER: -HIGH BLOOD PRESSURE /HYPOTHYROID

NOT SIGNIFICANT

## ANTHROPOMETRIC DATA &amp; BMI

HEIGHT IN METERS 1.74 mts

WEIGHT IN KGS. 59 Kgs

BMI 19 BMI &amp; Weight Status as follows: kg/sqmts

Below 18.5: Underweight

18.5 - 24.9: Normal

25.0 - 29.9: Overweight

30.0 and Above: Obese

## GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE NORMAL

PHYSICAL ATTITUDE NORMAL

GENERAL APPEARANCE / NUTRITIONAL STATUS HEALTHY

BUILT / SKELETAL FRAMEWORK AVERAGE

FACIAL APPEARANCE NORMAL

SKIN NORMAL

UPPER LIMB NORMAL

LOWER LIMB NORMAL

NECK NORMAL

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER



Scan to View Details



Scan to View Report



CLIENT CODE : C000138394

## CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
F-703, F-703, LADO SARAI, MEHRAULI  
SOUTH WEST DELHI  
NEW DELHI 110030  
DELHI INDIA  
8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email : customercare.thane@srl.in

PATIENT NAME : ANIRUDDHA ANANT MIRASHI

PATIENT ID : ANIRM170194181

ACCESSION NO : 0181VJ000691 AGE : 28 Years SEX : Male

ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18

REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF

CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
THYROID GLAND		NOT ENLARGED		
CAROTID PULSATION		NORMAL		
TEMPERATURE		NORMAL		
PULSE		78/MIN.REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID BRUIT		
RESPIRATORY RATE		NORMAL		
<b>CARDIOVASCULAR SYSTEM</b>				
BP		130/70 MM HG (SUPINE)		mm/Hg
PERICARDIUM		NORMAL		
APEX BEAT		NORMAL		
HEART SOUNDS		NORMAL		
MURMURS		ABSENT		
<b>RESPIRATORY SYSTEM</b>				
SIZE AND SHAPE OF CHEST		NORMAL		
MOVEMENTS OF CHEST		SYMMETRICAL		
BREATH SOUNDS INTENSITY		NORMAL		
BREATH SOUNDS QUALITY		VESICULAR (NORMAL)		
ADDED SOUNDS		ABSENT		
<b>PER ABDOMEN</b>				
APPEARANCE		NORMAL		
VENOUS PROMINENCE		ABSENT		
LIVER		NOT PALPABLE		
SPLEEN		NOT PALPABLE		
HERNIA		ABSENT		
<b>CENTRAL NERVOUS SYSTEM</b>				
HIGHER FUNCTIONS		NORMAL		
CRANIAL NERVES		NORMAL		
CEREBELLAR FUNCTIONS		NORMAL		
SENSORY SYSTEM		NORMAL		
MOTOR SYSTEM		NORMAL		
REFLEXES		NORMAL		
<b>MUSCULOSKELETAL SYSTEM</b>				
SPINE		NORMAL		
JOINTS		NORMAL		



Scan to View Details



Scan to View Report



CLIENT CODE : C000138394

## CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
F-703, F-703, LADO SARAI, MEHRAULI  
SOUTH WEST DELHI  
NEW DELHI 110030  
DELHI INDIA  
8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg

THANE, 400602

MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956

Email : customercare.thane@srl.in

PATIENT NAME : ANIRUDDHA ANANT MIRASHI

PATIENT ID : ANIRM170194181

ACCESSION NO : 0181VJ000691 AGE : 28 Years SEX : Male

ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18

REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF

CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## BASIC EYE EXAMINATION

CONJUNCTIVA	NORMAL
EYELIDS	NORMAL
EYE MOVEMENTS	NORMAL
CORNEA	NORMAL
DISTANT VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
DISTANT VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
NEAR VISION RIGHT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
NEAR VISION LEFT EYE WITHOUT GLASSES	WITHIN NORMAL LIMIT
COLOUR VISION	NORMAL

## SUMMARY

RELEVANT HISTORY	NOT SIGNIFICANT
RELEVANT GP EXAMINATION FINDINGS	NOT SIGNIFICANT
REMARKS / RECOMMENDATIONS	LOW FAT, LOW CALORIE, LOW CARBOHYDRATE, HIGH FIBRE DIET. REGULAR EXERCISE. REGULAR WALK FOR 30-40 MIN DAILY. REPEAT LIPID PROFILE AFTER 3 MONTHS OF DIET AND EXERCISE. USG - CANCEL

## Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-

The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology.

RBC AND PLATELET INDICES-

Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia (>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-

The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020) 106504

This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition. CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

## TEST INTERPRETATION

**Increase** in: Infections, Vasculitides, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR (>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr (62 if anemic) and in second trimester (0-70 mm/hr (95 if anemic). ESR returns to normal 4th week post partum.

**Decreased** in: Polycythemia vera, Sickle cell anemia



Scan to View Details



Scan to View Report





CLIENT CODE : C000138394

## CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
F-703, F-703, LADO SARAI, MEHRAULI  
SOUTH WEST DELHI  
NEW DELHI 110030  
DELHI INDIA  
8800465156

SRL Ltd

S.K. Tower, Hari Niwas, LBS Marg  
THANE, 400602  
MAHARASHTRA, INDIA

Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956  
Email : customercare.thane@srl.in

PATIENT NAME : ANIRUDDHA ANANT MIRASHI

PATIENT ID : ANIRM170194181

ACCESSION NO : 0181VJ000691 AGE : 28 Years SEX : Male

ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18

REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF

CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

## LIMITATIONS

False elevated ESR : Increased fibrinogen, Drugs (Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased : Poikilocytosis, (Sickle Cells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

## REFERENCE :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

## GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

## Increased in

Diabetes mellitus, Cushing's syndrome (10 - 15%), chronic pancreatitis (30%). Drugs: corticosteroids, phenytoin, estrogen, thiazides.

## Decreased in

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases (e.g., galactosemia), Drugs- insulin, ethanol, propranolol, sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

## NOTE:

Hypoglycemia is defined as a glucose of < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin (HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN (HbA1c), EDTA WHOLE BLOOD-Used For:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patient's metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to mg/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as  $eAG (mg/dl) = 28.7 * HbA1c - 46.7$

## HbA1c Estimation can get affected due to :

I. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin).

III. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addition are reported to interfere with some assay methods, falsely increasing results.

IV. Interference of hemoglobinopathies in HbA1c estimation is seen in

a. Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.

b. Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c. HbF > 25% on alternate platform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glycosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. Additional test HbA1c

## LIVER FUNCTION PROFILE, SERUM-

## LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels result from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in viral hepatitis, drug reactions, alcoholic liver disease. Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in gallstones getting into the bile ducts, tumors & scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of hemolytic or pernicious anemia, transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in biliary obstruction, osteoblastic bone tumors, osteomalacia, hepatitis, hyperparathyroidism, leukemia, lymphoma, Paget's disease, rickets, sarcoidosis etc. Lower-than-normal ALP levels seen in hypophosphatasia, malnutrition, protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system





CLIENT CODE : C000138394

**CLIENT'S NAME AND ADDRESS :**  
 ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
 F-703, F-703, LADO SARAI, MEHRAULI  
 SOUTH WEST DELHI  
 NEW DELHI 110030  
 DELHI INDIA  
 8800465156

SRL Ltd  
 S.K. Tower, Hari Niwas, LBS Marg  
 THANE, 400602  
 MAHARASHTRA, INDIA  
 Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956  
 Email : customercare.thane@srl.in

**PATIENT NAME : ANIRUDDHA ANANT MIRASHI** PATIENT ID : **ANIRM170194181**

ACCESSION NO : **0181VJ000691** AGE : 28 Years SEX : Male ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18 REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF CLIENT PATIENT ID :

Test Report Status	Final	Results	Biological Reference Interval	Units
--------------------	-------	---------	-------------------------------	-------

and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc

**BLOOD UREA NITROGEN (BUN), SERUM-** Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)  
 Causes of decreased level include Liver disease, SIADH.

**CREATININE, SERUM-** Higher than normal level may be due to:

- Blockage in the urinary tract
- Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
- Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia Gravis
- Muscular dystrophy

**URIC ACID, SERUM-**

**Causes of Increased levels:-** Dietary (High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome

**Causes of decreased levels-** Low Zinc intake, OCP, Multiple Sclerosis

**TOTAL PROTEIN, SERUM-**

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease

Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

**ALBUMIN, SERUM-**

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

**ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-**

Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A, B, O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

**MEDICAL**

**HISTORY-**

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

**\*\*End Of Report\*\***

Please visit [www.srlworld.com](http://www.srlworld.com) for related Test Information for this accession





CLIENT CODE : C000138394

## CLIENT'S NAME AND ADDRESS :

ACROFEMI HEALTHCARE LTD ( MEDIWHEEL )  
F-703, F-703, LADO SARAI, MEHRAULI  
SOUTH WEST DELHI  
NEW DELHI 110030  
DELHI INDIA  
8800465156

SRL Ltd  
S.K. Tower, Hari Niwas, LBS Marg  
THANE, 400602  
MAHARASHTRA, INDIA  
Tel : 9111591115, Fax : CIN - U74899PB1995PLC045956  
Email : customercare.thane@srl.in

PATIENT NAME : ANIRUDDHA ANANT MIRASHI

PATIENT ID : ANIRM170194181

ACCESSION NO : 0181VJ000691 AGE : 28 Years SEX : Male

ABHA NO :

DRAWN : RECEIVED : 14/10/2022 10:18

REPORTED : 29/10/2022 16:28

REFERRING DOCTOR : SELF

CLIENT PATIENT ID :

Test Report Status	Results	Biological Reference Interval	Units
Final			

## CONDITIONS OF LABORATORY TESTING &amp; REPORTING

1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
4. A requested test might not be performed if:
  - i. Specimen received is insufficient or inappropriate
  - ii. Specimen quality is unsatisfactory
  - iii. Incorrect specimen type
  - iv. Discrepancy between identification on specimen container label and test requisition form
5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
8. Test results cannot be used for Medico legal purposes.
9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

## SRL Limited

Fortis Hospital, Sector 62, Phase VIII,  
Mohali 160062



Scan to View Details



Scan to View Report